Across TCGA pan-cancer cohorts, ZFP36L1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZFP36L1 data layer compared with 19 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ZFP36L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ZFP36L1 expression acts as an unfavorable survival marker.

PDAC, CCRCC, and GBM are the cancer types where ZFP36L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.392	0.685	<.001	46	view →
CCRCC	OS	Tertile	All	0.871	1.000	.008	23	view →
GBM	DFS	Quartile	All	0.604	0.923	.003	11	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZFP36L1 tumor-vs-normal RNA expression · all ZFP36L1 data types